Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Transarterial radioembolization (TARE) has shown promising results in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). However, whether TARE can provide superior or comparable outcomes to tyrosine kinase inhibitor (TKI) in patients with HCC and PVTT remains unclear. We compared the outcomes of TARE and TKI therapy in treatment-naïve patients with locally advanced HCC and segmental or lobar PVTT. Methods: This multicenter study included 216 patients initially treated with TARE (n=124) or TKI (sorafenib or lenvatinib; n=92) between 2011 and 2021. Baseline characteristics were balanced using propensity score matching (PSM) or inverse probability of treatment weighting (IPTW). The primary outcome was overall survival (OS). The secondary outcomes included progression-free survival (PFS) and objective response rate (ORR). Results: In the unmatched cohort, the median OS of the TARE and TKI groups were 28.2 and 7.2 months, respectively (P<0.001), and the TARE group experienced significantly and independently longer OS compared to the TKI group (adjusted hazard ratio=0.41, 95% confidence interval=0.28–0.60, P<0.001). Similar results were observed in the study cohorts balanced with IPTW (P=0.003) or PSM (P=0.004). Although PFS was comparable between the two groups, the TARE group showed a trend of prolonged PFS in a subpopulation of patients with Vp1 or Vp2 PVTT (P=0.052). In the matched cohorts, the ORR of the TARE group was 53.0–56.7%, whereas that of the TKI group was 12.3–15.0%. Conclusions: For patients with advanced HCC with segmental or lobar PVTT and well-preserved liver function, TARE may provide superior OS compared to sorafenib or lenvatinib.
Abstract
Background/Aims: Transarterial radioembolization (TARE) has shown promising results in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). However, whether TARE can provide superior or comparable outcomes to tyrosine kinase inhibitor (TKI) in patients with HCC and PVTT remains unclear. We compared the outcomes of TARE and TKI therapy in treatment-naïve patients with locally advanced HCC and segmental or lobar PVTT. Methods: This multicenter study included 216 patients initially treated with TARE (n=124) or TKI (sorafenib or lenvatinib; n=92) between 2011 and 2021. Baseline characteristics were balanced using propensity score matching (PSM) or inverse probability of treatment weighting (IPTW). The primary outcome was overall survival (OS). The secondary outcomes included progression-free survival (PFS) and objective response rate (ORR). Results: In the unmatched cohort, the median OS of the TARE and TKI groups were 28.2 and 7.2 months, respectively (P<0.001), and the TARE group experienced significantly and independently longer OS compared to the TKI group (adjusted hazard ratio=0.41, 95% confidence interval=0.28–0.60, P<0.001). Similar results were observed in the study cohorts balanced with IPTW (P=0.003) or PSM (P=0.004). Although PFS was comparable between the two groups, the TARE group showed a trend of prolonged PFS in a subpopulation of patients with Vp1 or Vp2 PVTT (P=0.052). In the matched cohorts, the ORR of the TARE group was 53.0–56.7%, whereas that of the TKI group was 12.3–15.0%. Conclusions: For patients with advanced HCC with segmental or lobar PVTT and well-preserved liver function, TARE may provide superior OS compared to sorafenib or lenvatinib.
참고문헌 (35)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Thomas MB, "Hepatocellular carcinoma : consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting", J Clin Oncol, 28, pp.3994~4005 (2010)
- Llovet JM, "Natural history of untreated nonsurgical hepatocellular carcinoma : rationale for the design and evaluation of therapeutic trials", Hepatology, 29, pp.62~67 (1999)
- Lu J, "Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis : comparing east and west", Lancet Gastroenterol Hepatol, 4, pp.721~730 (2019)
- Takuji Torimura, "Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects", Clinical and Molecular Hepatology, 27(2), pp.236~245 (2021), 대한간학회[DOI]
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Bruix J, "Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma : subanalyses of a phase III trial", J Hepatol, 57, pp.821~829 (2012)
- Mazzaferro V, "Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma : a phase 2 study", Hepatology, 57, pp.1826~1837 (2013)
- Salem R, "Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC : The LEGACY Study", Hepatology, 74, pp.2342~2352 (2021)
- Sangro B, "Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages : a European evaluation", Hepatology, 54, pp.868~878 (2011)
- Salem R, "Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres : a comprehensive report of long-term outcomes", Gastroenterology, 138, pp.52~64 (2010)
- de la Torre MA, "A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization orsorafenib", Liver Int, 36, pp.1206~1212 (2016)
- Edeline J, "Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis", Eur J Nucl Med Mol Imaging, 43, pp.635~643 (2016)
- 김평화, "Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy", Korean Journal of Radiology, 20(3), pp.385~398 (2019), 대한영상의학회[DOI]
- Ahn JC, "Transarterial radioembolization versus systemic treatment for hepatocellular carcinoma with macrovascular invasion : Analysis of the US National Cancer Database", J Nucl Med, 62, pp.1692~1701 (2021)
- Martelletti C, "Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis : A propensity score and Bayesian analysis", J Dig Dis, 22, pp.496~502 (2021)
- Nisiewicz MJ, "Improved survival following transarterial radioembolization of infiltrative-appearance hepatocellular carcinoma", Abdom Radiol(NY), 46, pp.1958~1966 (2021)
- Vilgrain V, "Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma(SARAH) : an open-label randomised controlled phase 3 trial", Lancet Oncol, 18, pp.1624~1636 (2017)
- ChowPKH, "SIRveNIB : Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma", J Clin Oncol, 36, pp.1913~1921 (2018)
- Kulik LM, "Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis", Hepatology, 47, pp.71~81 (2008)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the american association for the study of liver diseases", Hepatology, 68, pp.723~750 (2018)
- Korean Liver Cancer Association (KLCA), "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clinical and Molecular Hepatology, 28(4), pp.583~705 (2022), 대한간학회
- The general rules for the clinical and pathological study of primary liver cancer., "Liver Cancer Study Group of Japan", Jpn J Surg, 19, pp.98~129 (1989)
- Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Xing M, "90Y radioembolization lung shunt fraction in primary and metastatic liver cancer as a biomarker for survival", Clin Nucl Med, 41, pp.21~27 (2016)
- Sangro B, "Transarterial chemoembolization and radioembolization", Semin Liver Dis, 34, pp.435~443 (2014)
- Yoon SM, "Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion : A randomized clinical trial", JAMA Oncol, 4, pp.661~669 (2018)
- Cho JY, "The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma", Liver Int, 34, pp.795~801 (2014)
- de Baere T, "Radioembolization: Same Player Shoots Again", pp.1~2 (2022), Springer
- Garin E, "Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma(DOSISPHERE-01) : a randomised, multicentre, open-label phase 2 trial", Lancet Gastroenterol Hepatol, 6, pp.17~29 (2021)
- Spreafico C, "Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion", J Hepatol, 68, pp.724~732 (2018)
- Finn RS, "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)